A subgroup analysis from the DEFINITIVE LE study for directional atherectomy
of infrapopliteal lesions showed high technical success and 1-year primary patency rates of 84%.
and specialty balloons, while not evaluated in this study, are commonly used to debulk or predictably dilate calcified lesions, which may minimize the need for provisional stents.
Lumivascular technology allows physicians, for the first time ever, to see from inside the artery during a directional atherectomy
procedure by using an imaging modality called optical coherence tomography, or OCT, which is displayed on the Lightbox console.
Lumivascular technology in the Pantheris catheter allows physicians, for the first time ever, to see from inside the artery during a directional atherectomy
procedure by using an imaging modality called optical coherence tomography, or OCT.
One method is directional atherectomy
, which can be employed, for example, by the TurboHawk Plaque Excision System by Coviden (Plymouth, MN).
has received CE Mark approval for Pantheris a system that combines directional atherectomy
capabilities with real-time intravascular visualization to remove plaque from blocked arteries.
The DEFINITIVE AR study is designed to evaluate the effect of treating a diseased vessel with a combination therapy that begins with directional atherectomy
to remove plaque build-up, followed by the use of a drug-coated balloon that releases anti-proliferative medication to inhibit restenosis.
Food and Drug Administration (FDA) 510(k) clearance for the HawkOne(TM) Directional Atherectomy
System in a new size for treating patients with peripheral artery disease (PAD).
Study Confirms Effectiveness of Directional Atherectomy
with SilverHawk [TM] and TurboHawk [TM] Devices as a Frontline Therapy when Treating PAD
Today's announcement, coupled with our recently announced joint development of guided directional atherectomy
, is further indication of HP's commitment to the interventional market.
OmniCath(r) is a directional atherectomy
catheter that employs deflecting non-traumatizing wires to anchor the cutting window at the atherectomy site.
The VIVA sponsored study is assessing outcomes for patients with significantly calcified and symptomatic femoropopliteal peripheral artery disease (PAD), following adjunctive use of directional atherectomy
and drug-coated balloon (DCB).